Skip to main content

Table 4 Statistical evaluation of the benefit of diverse chemotherapy regimens used for adjuvant treatment in patients with T4 UICC II

From: Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer

Group comparisons
  FUFOL FUFOL + Oxaliplatin Others + Oxaliplatin Other substances Substance unknown No chemotherapy
  Chemotheraphy Chi-   Chi-   Chi-   Chi-   Chi-   Chi-  
  group square Sig. square Sig. square Sig. square Sig. square Sig. square Sig.
Long Rank FUFOL    ,072 ,788 . . ,013 ,909 ,563 ,453 4,179 ,041
(Mantel-Cox) FUFOL + Oxaliplatin ,072 ,788    ,074 ,785 ,192 ,661 ,015 ,901 3,934 ,047
  Others + Oxaliplatin . . ,074 ,785    ,118 ,732 . . ,628 ,428
  Other substances ,013 ,909 ,192 ,661 ,118 ,732    ,223 ,636 4,370 ,037
  Substance unknown ,563 ,453 ,015 ,901    ,223 ,636    ,681 ,409
  No chemotheraphy 4,179 ,041 3,934 ,047 ,628 ,428 4,370 ,037 ,681 ,409